as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹727.5
Change
-15.0 (-2.02%)
Open
₹739.0
Prev. Close
₹742.5
Day High
₹746.55
Day Low
₹718.95
Volume Analysis
Traded
608,591
Delivered
261,164
Delivery %
42.91%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (25.0%)
Weaknesses (1)
- •High debt-to-equity ratio (1.53)
Opportunities (1)
- •Strong 3-year revenue growth (29.1%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹770.65 | ₹758.6 | ₹743.05 | ₹731.0 | ₹715.45 | ₹703.4 | ₹687.85 |
| Fibonacci | ₹758.6 | ₹748.06 | ₹741.54 | ₹731.0 | ₹720.46 | ₹713.94 | ₹703.4 |
| Camarilla | ₹735.09 | ₹732.56 | ₹730.03 | ₹731.0 | ₹724.97 | ₹722.44 | ₹719.91 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-2.63%
1 Month
-5.72%
3 Months
—
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
10.95%
Net margin 8.87% × asset turnover 0.42x × equity multiplier 2.94x
Company Overview
Sector
Healthcare
Market Cap
₹98,193 Cr
P/E (TTM)
111.0
ROE
12.7%
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 22 Sep 2026. Not investment advice.
TopFund Analysis
Manipal Health Enterpri L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 50/100. The strongest factor is Cash Flow (88/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (25.0%); high debt-to-equity ratio (1.53). Strong 3-year revenue growth (29.1%).
TopFund Score — Fundamentals Quality
50/100 — AverageData confidence: 73/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 76.8% CAGR over last 5 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Manipal Hospitals fully redeemed ₹5,310 crore NCDs using IPO proceeds on September 17, 2026.
IPO proceeds used to fully redeem subsidiary NCDs of Rs 5,310 crore plus interest and prepayment costs.
Newspaper Advertisement for information regarding the dispatch of the 16th AGM Notice and other related information including e-voting.
16th AGM on September 29, 2026; annual report and notice web link shared.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Sales + | 2,238 | 2,882 | 3,091 |
| Expenses + | 1,651 | 2,191 | 2,354 |
| Operating Profit | 586 | 691 | 737 |
| OPM % | 26.0% | 24.0% | 24.0% |
| Other Income + | 30 | 27 | 59 |
| Interest | 132 | 289 | 293 |
| Depreciation | 141 | 185 | 187 |
| Profit before tax | 344 | 244 | 315 |
| Tax % | 26.0% | 24.0% | 23.0% |
| Net Profit + | 254 | 187 | 243 |
| EPS in Rs | 2 | 2 | 2 |
| Raw PDF | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 1,813 | 3,975 | 4,806 | 6,172 | 8,242 | 10,336 |
| Expenses + | 1,483 | 3,054 | 3,527 | 4,489 | 6,115 | 7,725 |
| Operating Profit | 330 | 921 | 1,279 | 1,683 | 2,127 | 2,611 |
| OPM % | 18.0% | 23.0% | 27.0% | 27.0% | 26.0% | 25.0% |
| Other Income + | -47 | 293 | -48 | -86 | 134 | 111 |
| Interest | 205 | 326 | 329 | 455 | 512 | 864 |
| Depreciation | 183 | 256 | 315 | 397 | 507 | 680 |
| Profit before tax | -105 | 632 | 586 | 745 | 1,242 | 1,178 |
| Tax % | 30.0% | 14.0% | 27.0% | 28.0% | 13.0% | 22.0% |
| Net Profit + | -138 | 542 | 429 | 533 | 1,082 | 917 |
| EPS in Rs | -20 | 72 | 57 | 71 | 28 | 8 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Reserves | 1,064 | 2,732 | 3,166 | 3,940 | 5,770 | 8,190 |
| Borrowings + | 1,575 | 2,017 | 2,184 | 5,130 | 6,385 | 12,863 |
| Other Liabilities + | 1,316 | 2,521 | 2,337 | 1,612 | 1,658 | 3,446 |
| Total Liabilities | 4,024 | 7,346 | 7,763 | 10,757 | 13,890 | 24,735 |
| Fixed Assets + | 2,278 | 4,582 | 4,784 | 6,934 | 9,826 | 18,753 |
| CWIP | 412 | 1,089 | 1,033 | 1,266 | 614 | 795 |
| Investments | 551 | 768 | 1,038 | 1,121 | 1,776 | 2,675 |
| Other Assets + | 784 | 907 | 908 | 1,436 | 1,675 | 2,511 |
| Total Assets | 4,024 | 7,346 | 7,763 | 10,757 | 13,890 | 24,735 |
| Equity Capital | 69 | 76 | 76 | 76 | 77 | 236 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 426 | 805 | 1,149 | 1,389 | 1,570 | 2,078 |
| Cash from Investing Activity + | -188 | -1,711 | -994 | -870 | -2,544 | -7,025 |
| Cash from Financing Activity + | -280 | 941 | -144 | -250 | 904 | 4,954 |
| Net Cash Flow | -42 | 34 | 12 | 268 | -70 | 8 |
| CFO/OP | 106 | 98 | 105 | 100 | 87 | 96 |
| Free Cash Flow | 334 | 629 | 823 | 1,394 | 520 | 767 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Aug 2026 | |
|---|---|
| Public | 18.81% |
| Promoters | 72.08% |
| Government | 0.26% |
| FII | 3.66% |
| DII | 5.2% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Manipal Health Enterpri L (this stock) | 98,193 | 111.0 | — | 12.7% |
| Max Healthcare Ins Ltd | 98,694 | 65.9 | 9.22 | 14.7% |
| Aurobindo Pharma Ltd | 98,939 | 26.2 | 2.64 | 10.1% |
| Lupin Limited | 95,788 | 16.1 | 4.26 | 28.7% |
| Dr. Reddy S Laboratories | 101,096 | 31.4 | 2.67 | 11.2% |
| Mankind Pharma Limited | 102,225 | 47.9 | 6.27 | 13.1% |
| Laurus Labs Limited | 108,438 | 99.2 | 20.44 | 18.3% |
Which Mutual Funds Hold Manipal Health Enterpri L?
Frequently Asked Questions about Manipal Health Enterpri L
Manipal Health Enterpri L (MANIPALHOS) closed at ₹727.5 on NSE on 25 September 2026, down 15.0 (2.02%) from the previous close.
Manipal Health Enterpri L trades on the NSE (National Stock Exchange of India) under the symbol MANIPALHOS.
Manipal Health Enterpri L has a trailing twelve-month P/E (price-to-earnings) ratio of 111.0.
Manipal Health Enterpri L has a dividend yield of 0.0%.
Manipal Health Enterpri L's 52-week high is ₹815.0 and its 52-week low is ₹625.0.
Manipal Health Enterpri L has a market capitalisation of ₹98,193 crore.
Manipal Health Enterpri L has a TopFund Quality Score of 50/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Manipal Health Enterpri L?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.